L Roman

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

Franco M. Muggia, John D. Hainsworth, Susan Jeffers et al. · Journal of Clinical Oncology · 1997 · 656 citations

Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')

Luca Gianni, Tadeusz Pieńkowski, Y-H Im et al. · Cancer Research · 2010 · 67 citations

Breast Oncology, Cancer Management, Pathology +16

Phase II Study of Liposomal Doxorubicin in Advanced Gynecologic Cancers

Valerie P. Israel, Augustin A. Garcia, L Roman et al. · Gynecologic Oncology · 2000 · 59 citations

Oncology, Medicine, Pathology +5

S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC).

Luca Gianni, Giampaolo Bianchini, Astrid Kiermaier et al. · Cancer Research · 2011 · 49 citations

Biomarker Analyses, Breast Oncology, Immunology +22

Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer

Robert L. Capizzi, L Roman, S. Tjulandin et al. · Journal of Clinical Oncology · 2008 · 25 citations

Breast Oncology, Pharmacotherapy, Cardiovascular Toxicity +16